Praluent (Sanofi-Aventis Canada, 75 mg, 150 mg, 300 mg) Product Monograph

Recent Major Label Changes

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes ................................................................................................... 2

Table of Contents ................................................................................................................... 2

Part 1: Healthcare Professional Information ........................................................................... 5

1. 1.

   Indications ....................................................................................................................... 5

   1.1. Pediatrics .................................................................................................................. 5

   1.2. Geriatrics .................................................................................................................. 5

2. 2. Contraindications ............................................................................................................ 5
3. 4.

   Dosage and Administration ............................................................................................. 5

   4.2. Recommended Dose and Dosage Adjustment ......................................................... 5

   4.4. Administration .......................................................................................................... 6

   4.5. Missed Dose ............................................................................................................. 7

4. 5. Overdose ......................................................................................................................... 7
5. 6. Dosage Forms, Strengths, Composition, and Packaging ................................................... 7
6. 7.

   Warnings and Precautions ............................................................................................... 8

   Hepatic/Biliary/Pancreatic .................................................................................................... 8

   Immune ................................................................................................................................ 9

   Renal ..................................................................................................................................... 9

   Reproductive Health ............................................................................................................. 9

   7.1. Special Populations .................................................................................................. 9

   7.1.1. Pregnancy ........................................................................................................ 9

   7.1.2. Breastfeeding .................................................................................................. 9

   7.1.3. Pediatrics ....................................................................................................... 10

   7.1.4. Geriatrics ....................................................................................................... 10

7. 8.

   Adverse Reactions ......................................................................................................... 10

   8.1. Adverse Reaction Overview .................................................................................... 10

   8.2. Clinical Trial Adverse Reactions .............................................................................. 10

   8.3. Less Common Clinical Trial Adverse Reactions ....................................................... 14

   8.5. Post-Market Adverse Reactions ............................................................................. 15

8. 9.

   Drug Interactions ........................................................................................................... 15

   9.2. Drug Interactions Overview .................................................................................... 15

   9.3. Drug-Behaviour Interactions .................................................................................. 15

   9.4. Drug-Drug Interactions ........................................................................................... 16

   9.5. Drug-Food Interactions........................................................................................... 16

   9.6. Drug-Herb Interactions ........................................................................................... 16

   9.7. Drug-Laboratory Test Interactions ......................................................................... 16

9. 10.

   Clinical Pharmacology ................................................................................................... 16

   10.1. Mechanism of Action .............................................................................................. 16

   10.2. Pharmacodynamics ................................................................................................ 16

   10.3. Pharmacokinetics ................................................................................................... 16

   10.4. Immunogenicity ...................................................................................................... 18

10. 11. Storage, Stability, and Disposal ...................................................................................... 19

Part 2: Scientific Information ................................................................................................ 20

1. 13. Pharmaceutical Information .......................................................................................... 20
2. 14.

   Clinical Trials .................................................................................................................. 21

   14.1. Clinical Trials by Indication ..................................................................................... 21

3. 16. Non-Clinical Toxicology .................................................................................................. 38

Patient Medication Information ........................................................................................... 40

INSTRUCTIONS FOR USE ....................................................................................................... 45

PRALUENT (alirocumab) 75 mg solution for injection in a pre-filled pen with activation button ...................................................................................................................................... 45

PRALUENT (alirocumab) 75 mg solution for injection in a pre-filled pen without activation button ........................................................................................................................... 52

PRALUENT (alirocumab) 150 mg solution for injection in a pre-filled pen with activation button .................................................................................................................................. 60

PRALUENT (alirocumab) 150 mg solution for injection in a pre-filled pen without activation button .................................................................................................................................. 67

PRALUENT (alirocumab) 300 mg solution for injection in a pre-filled pen without activation button ........................................................................................................................... 76

Part 1: Healthcare Professional Information

1. Indications

Prevention of Cardiovascular Events

PRALUENT (alirocumab injection) is indicated in combination with a maximum tolerated dose of a statin, with or without other lipid lowering therapies, to reduce the risk of myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.

Primary Hyperlipidemia

PRALUENT (alirocumab injection) is indicated for the reduction of low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia (heterozygous familial and non-familial):

• As an adjunct to diet and statin therapy, with or without other lipid-lowering therapies;
• As an adjunct to diet, as monotherapy or in combination with other non-statin lipid-modifying therapies, in patients for whom a statin is contraindicated.

1.1. Pediatrics

The efficacy and safety of PRALUENT in these patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

1.2. Geriatrics

In primary hypercholesterolemia controlled studies, 1158 patients (34.7 %) treated with PRALUENT were ≥ 65 years of age, including 241 patients (7.2 %) ≥ 75 years of age. In the cardiovascular outcomes study, 2505 patients (26.5%) treated with PRALUENT were ≥ 65 years of age, including 493 patients (5.2%) ≥ 75 years of age. No overall differences in safety or efficacy were observed between these patients and younger patients (see 7 Warnings and Precautions, 7.1 Special Populations, 7.1.4 Geriatrics).

2. Contraindications

PRALUENT is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see the 6 Dosage Forms, Strengths, Composition, and Packaging section of the product monograph.

4. Dosage and Administration

4.2. Recommended Dose and Dosage Adjustment

The recommended starting dose of PRALUENT is 75 mg once every 2 weeks (Q2W) administered subcutaneously, since the majority of patients achieve sufficient LDL-C reduction with this dosage. Alternatively, 300 mg once every 4 weeks (monthly) may be administered subcutaneously for patients who prefer less frequent dosing.

Measure LDL-C levels within 4 to 8 weeks of initiating PRALUENT to assess response and adjust the dose, if needed. For patients receiving PRALUENT 300 mg every 4 weeks, measure LDL-C just prior to the next scheduled dose of initiating PRALUENT, since LDL-C levels in some patients can vary considerably between doses with this regimen (see 14 Clinical Trials, CHOICE I study).

If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks.

Special Populations

Pediatric patients

The efficacy and safety of PRALUENT in these patients have not been established (see 1 Indications, 1.1 Pediatrics)

Elderly patients

No dose adjustment is needed for elderly patients.

Hepatic impairment

No dose adjustment is needed for patients with mild or moderately impaired hepatic function. No data are available in patients with severe hepatic impairment (see 10 Clinical Pharmacology, Special Populations and Conditions).

Renal impairment

No dose adjustment is needed for patients with mild or moderately impaired renal function. No data are available in patients with severe renal impairment (see 10 Clinical Pharmacology, Special Populations and Conditions – Renal Insufficiency).

Body weight

No dose adjustment is needed in patients based on weight (see 10 Clinical Pharmacology, Special Populations and Conditions – Obesity).

4.4. Administration

PRALUENT is administered as a subcutaneous injection into the thigh, abdomen, or upper arm, using a single-use pre-filled pen.

For the PFP with activation button, allow the 75mg/mL or 150 mg/mL pen to warm to room temperature for 30-40 minutes.

For the PFP without activation button, allow the 75mg/mL, 150 mg/mL, or 300 mg/mL pen to warm to room temperature for 45 minutes.

The patient may either self-inject alirocumab, or a caregiver may administer alirocumab, after guidance has been provided by a healthcare professional on proper subcutaneous injection technique.

To administer the 300 mg dose, give either one 300 mg PRALUENT injection or two 150 mg PRALUENT injections consecutively at two different injection sites. The 300 mg dose may be self-administered in thigh or abdomen. Only upper arm administrations require the help of a caregiver.

It is recommended to rotate the injection site with each injection.

PRALUENT should not be injected into areas of active skin disease or injury, such as sunburns, skin rashes, inflammation, or skin infections.

Do not co-administer PRALUENT with other injectable drugs at the same injection site.

Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration. If the solution is discoloured or contains visible particulate matter, the solution should not be used.

Patients and caregivers should receive guidance on proper subcutaneous injection technique, including aseptic technique, and how to use the PFP correctly (see Instructions for Use leaflet).

Patients and caregivers should be reminded to read the patient information leaflet and Instructions for Use leaflet carefully before administration of PRALUENT.

Patients and caregivers should be cautioned that the PFP must not be re-used, and instructed on how to safely discard after use.

4.5. Missed Dose

If an every 2-week dose is missed, the patient should administer the injection as soon as possible (within 7 days from the missed dose), and thereafter resume treatment two weeks from the day of the missed dose, keeping the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to wait until the next dose on the original schedule.

If an every 4-week dose is missed, instruct the patient to administer the injection within 7 days of the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date

5. Overdose

In controlled clinical studies, no safety issues were identified with more frequent PRALUENT dosing than the recommended Q2W dosing schedule.

1. 6. Dosage Forms, Strengths, Composition, and Packaging

To help ensure the traceability of biologic products, healthcare professionals should record both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

Table 1 – Dosage Forms, Strengths, and Composition

PRALUENT is a clear, colourless to pale yellow solution, with a pH of about 6.0.

PRALUENT is supplied as a sterile, preservative-free solution for injection, in a single-use pre-filled pen (PFP).

75 mg solution for injection in pre-filled pen

• The syringe components are assembled into a single-use pre-filled pen with a blue cap and a light green activation button
• The syringe components are assembled into a single-use pre-filled pen with a blue cap and without an activation button

150 mg solution for injection in pre-filled pen

• The syringe components are assembled into a single-use pre-filled pen with a blue cap and a dark grey activation button.
• The syringe components are assembled into a single-use pre-filled pen with a blue cap and without an activation button

300 mg solution for injection in pre-filled pen

• The syringe components are assembled into a single-use pre-filled pen with a blue cap and no activation button.

Each 1 mL PFP contains 75 mg or 150 mg alirocumab. Each 2 mL PFP contains 300 mg alirocumab.

Each 75 mg/mL, 150 mg/mL and 300 mg/2 mL PFP contains histidine, sucrose, polysorbate 20, and water for injection (USP), to pH 6.0.

PRALUENT 75 mg/mL or 150 mg/mL solution for injection in single-use PFP is supplied in a siliconized 1 mL or 2 mL Type 1 clear glass syringe. The rubber needle shield does not contain natural latex.

Pack size of 75 or 150 mg PFP: 1, 2, or 6 per carton.

Pack size of 300 mg PFP: 1 or 3 per carton.

7. Warnings and Precautions

Hepatic/Biliary/Pancreatic

Hepatic Impairment:

The safety and efficacy of PRALUENT in patients with severe hepatic impairment have not been studied (see 8 Adverse Reactions).

Immune

Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including serious allergic reactions (i.e., angioedema, hypersensitivity reactions requiring hospitalization, nummular eczema, hypersensitivity vasculitis) have been reported with PRALUENT treatment (see 8 Adverse Reactions). If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT and initiate appropriate treatment according to standard of care, and monitor until signs and symptoms resolve (see 2 Contraindications).

Renal

Renal Impairment:

The safety and efficacy of PRALUENT in patients with severe renal impairment, including end-stage renal disease, have not been studied.

Reproductive Health

• Fertility

  No data are available on the effect of PRALUENT on human fertility. Animal studies did not show any effects on fertility endpoints (see 16 16. Non-Clinical Toxicology).

7.1. Special Populations

7.1.1. Pregnancy

No studies have been conducted with PRALUENT in pregnant women and data from clinical use are very limited.

Studies in monkeys showed that alirocumab crosses the placental barrier and is pharmacologically active in infants exposed during organogenesis through parturition. A suppression of the humoral immune response to keyhole limpet hemocyanin (KLH) antigen was observed in offspring of exposed animals. Animal studies did not demonstrate any additional effects on pregnancy or neonatal/infant development (see 16 16. Non-Clinical Toxicology).

Animal studies are not always predictive of human response. Therefore, it is not known whether PRALUENT can cause fetal harm when administered to a pregnant woman. PRALUENT is used in combination with maximally tolerated statin. Statin Product Monographs recommend discontinuation when a patient becomes pregnant, therefore PRALUENT should also be discontinued (see the Special Populations section of the relevant statin Product Monograph).

7.1.2. Breastfeeding

There is no information regarding the presence of PRALUENT in human breast milk, the effects on the breastfed infant, or the effects on milk production. A risk to breastfed newborns and infants cannot be excluded. Because many drugs and immunoglobulins are excreted in human milk, the use of PRALUENT is not recommended in breastfeeding women.

7.1.3. Pediatrics

The efficacy and safety of PRALUENT in pediatric patients have not been established (see 1 Indications, 1.1 Pediatrics); therefore, Health Canada has not authorized an indication for pediatric use. Clinical trial experience in the pediatric population is limited to 8 patients aged 9-11 (<12) years and 10 patients aged 12-17 (≥12-<18) years with homozygous familial hypercholesterolemia (HoFH), treated with 75mg (BW<50kg) or 150mg (BW>50kg) of PRALUENT Q2W for up to 48 weeks. No data are available in patients younger than 9 years of age.

7.1.4. Geriatrics

In controlled studies, 1158 patients (34.7 %) treated with PRALUENT were ≥ 65 years of age and 241 patients (7.2 %) treated with PRALUENT were ≥ 75 years of age. No overall differences in safety or efficacy were observed between age classes but data are limited in patients over 75 years of age.

8. Adverse Reactions

8.1. Adverse Reaction Overview

The safety data described below reflect exposure to PRALUENT in 2476 patients (2758.5 patient-years of exposure), the majority with high or very high cardiovascular risk, treated with PRALUENT at a dose of 75 or 150 mg, administered subcutaneously once every 2 weeks (Q2W), for a treatment duration of up to 18 months (including 1999 patients exposed to PRALUENT for at least 52 weeks, and 639 patients exposed to PRALUENT for at least 76 weeks). The safety data are based on pooled results from nine placebo-controlled studies (four phase 2 and five phase 3 studies, all in patients on background statin).

Serious adverse events occurred in 13.7% of patients treated with PRALUENT and 14.3% of patients in the placebo group.

In ten phase 3 controlled trials, involving patients with primary hypercholesterolemia, the most common adverse reactions were local injection site reactions (including erythema/redness, itching, swelling, pain/tenderness), upper respiratory tract signs and symptoms and pruritus (itch). Adverse reactions led to discontinuation of treatment in 5.3% of patients treated with PRALUENT and 5.1% of patients in the placebo group. The most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and injection site reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively).

The safety profile of PRALUENT derived from the cardiovascular outcomes study (ODYSSEY OUTCOMES) was consistent with the overall safety profile described in the phase 3 controlled trials.

8.2. Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. Therefore, the frequencies of adverse reactions observed in the clinical trials may not reflect frequencies observed in clinical practice and should not be compared to frequencies reported in clinical trials of another drug.

Table 2 – Adverse Events Occurring in ≥ 1% of Patients Treated with PRALUENT and More Frequently than with Placebo in the Pool of 10 Hyperlipidemia Placebo-Controlled Trials

The safety profile of alirocumab in the ezetimibe-controlled studies (COMBO II, MONO, ALTERNATIVE) was consistent with the safety profile in the placebo-controlled studies with no additional adverse reactions identified.

Table 3 – Adverse Events Occurring in > 1% of Patients Treated with PRALUENT and More Frequently than with Placebo in the Cardiovascular Outcomes Study (ODYSSEY OUTCOMES)

Injection site reactions

Injection site reactions, including erythema/redness, itching, swelling, and pain/tenderness were reported in 7.2% of patients treated with PRALUENT vs. 5.1% in the placebo group. Most injection site reactions were transient and of mild intensity. The discontinuation rate due to local injection site reactions was 0.2% versus 0.4% for PRALUENT and placebo, respectively.

In a 48-week placebo-controlled trial evaluating injection of PRALUENT 300 mg every 4 weeks (Q4W) or 75 mg every 2 weeks (Q2W) , in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind (see 14 Clinical Trials, CHOICE I study), local injection site reactions were reported more frequently in patients treated with PRALUENT 300 mg Q4W as compared to those receiving PRALUENT 75 mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively). The discontinuation rate due to injection site reactions was 0.7% in patients treated with PRALUENT 300 mg Q4W versus 0% in the placebo treatment group.

In the cardiovascular outcomes study (ODYSSEY OUTCOMES), injection site reactions also occurred more frequently in alirocumab-treated patients than in placebo-treated patients (3.8% alirocumab versus 2.1% placebo).

Allergic reactions

General allergic reactions were reported more frequently in the PRALUENT group than in the placebo group (8.6% vs 7.8% respectively), mainly due to a difference in the incidence of pruritus. The proportion of patients who discontinued treatment due to allergic reactions was higher among those treated with PRALUENT (0.6% versus 0.2%). In addition, rare and sometimes serious allergic reactions, such as hypersensitivity, nummular eczema, and hypersensitivity vasculitis have been reported in controlled clinical studies.

Neurocognitive Events

Neurocognitive events were reported in 0.8% of patients treated with PRALUENT and 0.7% of the placebo group patients. Confusion or memory impairment were each reported in 0.2% of patients treated with PRALUENT and in <0.1% (for each) in the placebo group patients. The majority of neurocognitive events were non-serious. See 14 Clinical Trials for the results of the Neurocognitive Function study (R727-CL-1532).

Liver Enzyme Abnormalities

Hepatic abnormalities (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of the placebo group patients. Increases in serum alanine transaminase (ALT) to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of the placebo group patients.

Low LDL-C levels

In the pool of the placebo- and active-controlled studies using an every 2 week or every 4 week dosing interval, 914 of 3913 patients (23.4 %) treated with PRALUENT had two consecutive values of LDL-C <0.65 mmol/L (25 mg/dL), including 335 patients (8.6 %) with two consecutive values of LDL-C <0.39 mmol/L (15 mg/dL). LDL-C values < 0.65 mmol/L (25 mg/dL) and <0.39 mmol/L (15 mg/dL) were observed more frequently in patients treated with the PRALUENT 150 mg Q2W or 300 mg Q4W dosing regimens.

Although adverse consequences of very low LDL-C were not identified in alirocumab trials, the long-term effects of sustained very low levels of LDL-C are unknown.

8.3. Less Common Clinical Trial Adverse Reactions

In the pooled placebo- and ezetimibe-controlled studies, the following adverse reactions were observed with a frequency of less than 1% and at a higher frequency in the PRALUENT arm compared to control (control vs. PRALUENT):

Blood and lymphatic system disorders: neutropenia (<0.1% vs. 0.2%)

Cardiac disorders: palpitations (<0.1% vs. 0.2%)

Gastrointestinal disorders: abdominal pain (0.1% vs. 0.2%), constipation (0.1% vs. 0.2%)

General disorders and administration site conditions: fatigue (0.5% vs. 0.6%), asthenia (0.1% vs. 0.3%), injection site erythema (<0.1% vs. 0.1%)

Immune system disorders: hypersensitivity (0.1% vs. 0.2%)

Infections and infestations: urinary tract infection (0% vs. 0.1%)

Injury, poisoning and procedural complications: accidental overdose (0.5% vs. 0.6%)

Investigations: alanine aminotransferase increased (0.3% vs. 0.4%), gamma-glutamyltransferase increased (<0.1% vs. 0.1%)

Metabolism and nutrition disorders: decreased appetite (<0.1% vs. 0.1%)

Musculoskeletal and connective tissue disorders: muscle spasms (0.4% vs. 0.6%)

Nervous system disorders: hypoesthesia (<0.1% vs. 0.2%)

Respiratory, thoracic and mediastinal disorders: epistaxis (<0.1% vs. 0.1%)

Skin and subcutaneous tissue disorders: pruritus (0.1% vs. 0.3%), rash (0.1% vs. 0.3%)

8.5. Post-Market Adverse Reactions

The following additional adverse reactions have been reported during post-market use of PRALUENT.

General disorders and administration site conditions: Flu-like illness

Skin and subcutaneous tissue disorders: Angioedema

9. Drug Interactions

9.2. Drug Interactions Overview

No formal drug-drug interaction studies have been conducted for alirocumab, nor have any studies been conducted to assess interactions with food/diet, herbal products or lifestyle.

9.3. Drug-Behaviour Interactions

The interaction of PRALUENT with individual behavioural risks (e.g. cigarette smoking, cannabis use, and/or alcohol consumption) has not been studied.

9.4. Drug-Drug Interactions

Effects of alirocumab on other drugs

In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab.

9.5. Drug-Food Interactions

Interactions with food have not been established.

9.6. Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7. Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10. Clinical Pharmacology

10.1. Mechanism of Action

Alirocumab is a fully human monoclonal antibody (Immunoglobulin IgG1 isotype) that binds with high affinity and specificity to proprotein convertase subtilisin kexin type 9 (PCSK 9). Alirocumab is produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.

PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.

10.2. Pharmacodynamics

Alirocumab reduced free PCSK9 in a concentration-dependent manner. Following a single subcutaneous administration of alirocumab 75 or 150 mg, maximal suppression of free PCSK9 occurred within 4 to 8 hours. Free PCSK9 concentrations returned to baseline when alirocumab concentrations decreased below the limit of quantitation.

10.3. Pharmacokinetics

Table 4 – Summary of alirocumab pharmacokinetic parameters in adults with established cardiovascular disease, and primary hyperlipidemia (heterozygous familial and non-familial)

^a: Median (Min-Max)

Absorption

After subcutaneous (SC) administration of 75 mg to 300 mg alirocumab, median times to maximum serum concentration (t_max) were 3-7 days.

The pharmacokinetics (PK) of alirocumab after single SC administration of 75 mg into the abdomen, upper arm or thigh were similar.

The absolute bioavailability of alirocumab after SC administration was about 85% as determined by population PK analysis.

A slightly greater than dose proportional increase was observed, with a 2.1- to 2.7-fold increase in total alirocumab concentrations for a 2-fold increase in dose from 75 mg every 2 weeks to 150 mg every 2 weeks. Monthly exposure with 300 mg every 4 weeks treatment was similar to that of 150 mg every 2 weeks.

Steady state was reached after 2 to 3 doses with an accumulation ratio up to a maximum of about 2-fold.

Distribution

Following IV administration, the volume of distribution was about 0.04 to 0.05 L/kg indicating that alirocumab is distributed primarily in the circulatory system.

Metabolism

Specific metabolism studies were not conducted, because alirocumab is a protein. Alirocumab is expected to degrade to small peptides and individual amino acids.

Elimination

Two elimination phases were observed for alirocumab. At low concentrations, the elimination is predominately through saturable binding to target (PCSK9), while at higher concentrations the elimination of alirocumab is largely through a non-saturable proteolytic pathway.

Based on a population pharmacokinetic analysis, the median apparent half-life of alirocumab at steady state was 17 to 20 days in patients receiving alirocumab at subcutaneous doses of 75 mg Q2W or 150 mg Q2W. When co-administered with a statin, the median apparent half-life of alirocumab was reduced to 12 days

Special populations and conditions

• Pediatrics: The pharmacokinetic profile of alirocumab has not been established in pediatric patients (see 1 INDICATIONS, 1.1 Pediatrics). Health Canada has not authorized an indication

  • for pediatric use.
• Geriatrics: Based on a population pharmacokinetic analysis, age was associated with a small difference in alirocumab exposure at steady state, with no impact on efficacy or safety.
• Sex: Based on a population pharmacokinetic analysis, gender was found not to significantly influence alirocumab pharmacokinetics.
• Ethnic origin: Based on a population pharmacokinetic analysis, race was found not to significantly influence alirocumab pharmacokinetics.
• Hepatic Insufficiency: In a phase 1 study, after administration of a single 75 mg SC dose, alirocumab pharmacokinetic profiles in subjects with mild and moderate hepatic impairment were similar as compared to subjects with normal hepatic function. No data are available in patients with severe hepatic impairment.
• Renal Insufficiency: Since monoclonal antibodies are not known to be eliminated via renal pathways, renal function is not expected to impact the pharmacokinetics of alirocumab. No data are available in patients with severe renal impairment.
• Obesity: Based on a population pharmacokinetic analysis, body weight was associated with a small difference in alirocumab exposure, with no significant influence on efficacy or safety.

10.4. Immunogenicity

Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies in the studies described below with the incidences of antibodies in other studies or to other products may be misleading.

In the ODYSSEY OUTCOMES trial, 5.5% of patients treated with alirocumab 75 mg and/or 150 mg every 2 weeks (Q2W) had anti-drug antibodies (ADA) detected after initiating treatment compared with 1.6% of patients treated with placebo. Persistent ADA responses were observed in 0.7% of patients treated with alirocumab and 0.4% of patients treated with placebo. Neutralizing antibody (NAb) responses were observed in 0.5% of patients treated with alirocumab and in <0.1% of patients treated with placebo.

Anti-drug antibody responses, including NAb, were low titer and did not appear to have a clinically meaningful impact on the efficacy or safety of alirocumab, except for a higher rate of injection site reactions in patients with treatment emergent ADA compared to patients who were ADA negative (7.5% vs 3.6%). The long-term consequences of continuing alirocumab treatment in the presence of ADA are unknown.

In a pool of ten placebo-controlled and active-controlled trials of patients treated with alirocumab 75 mg and/or 150 mg Q2W as well as in a separate clinical study of patients treated with alirocumab 75 mg Q2W or 300 mg every 4 weeks (including some patients with dose adjustment to 150 mg Q2W), the incidence of detecting ADA and NAb was consistent with the results from the ODYSSEY OUTCOMES trial.

1. 11. Storage, Stability, and Disposal

Store in a refrigerator at 2°C to 8°C (36°to 46° F). Do not freeze.

Store in the outer carton in order to protect from light.

Do not expose to extreme heat.

Prior to use:

• For the PFP with activation button, allow the 75mg/mL or 150 mg/mL pen to warm to room temperature for 30-40 minutes.
• For the PFP without activation button, allow the 75mg/mL, 150 mg/mL, or 300 mg/mL pen to warm to room temperature for 45 minutes.

PRALUENT should be used as soon as possible after it has warmed up to room temperature. Time out of refrigeration should not exceed 30 days at 25^oC.

After use, place the PFP into a puncture-resistant container and discard as required by local (provincial) regulations. Do not recycle the container. Always keep the container out of the reach of children.

Part 2: Scientific Information

13. Pharmaceutical Information

Proper name: Alirocumab

Molecular mass: 146 kDa

Physicochemical properties: Alirocumab is a sterile, preservative-free, clear, colourless to pale yellow solution for subcutaneous injection

Drug Substance

Alirocumab is a fully human monoclonal antibody (IgG1 isotype) that targets proprotein convertase subtilisin kexin type 9 (PCSK 9). Alirocumab is produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.

Alirocumab consists of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a fully human kappa light chain. A single N-linked glycosylation site is located in each heavy chain within the CH2 domain of the Fc constant region of the molecule. The variable domains of the heavy and light chains combine to form the PCSK9 binding site within the antibody. Alirocumab has an approximate molecular weight of 146 kDa.

Figure 1 – Schematic Representation of the Structure of Alirocumab*

* Orange= Location of intra-chain and inter-chain disulfide bonds; Green=Heavy chains; Blue=Light chains; Cyan= Fc domain glycosylation site; CH = constant region of the heavy chain; CL = constant region of the light chain; VH = variable region of the heavy chain; VL = variable region of the light chain.

14. Clinical Trials

14.1. Clinical Trials by Indication

Prevention of Cardiovascular Events

Table 5 – Summary of Trial Design and Patient Demographics for Prevention of Cardiovascular Events

Study demographics and trial design

The cardiovascular outcomes study (ODYSSEY OUTCOMES) was a multicentre, double-blind, placebo-controlled, event-driven trial, which included 18,924 adult patients (9462 alirocumab; 9462 placebo) that were followed for a median duration of 33 months (24 months to 5 years). Patients had experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with a lipid-modifying-therapy (LMT) regimen that was statin-intensive (i.e., atorvastatin 40 or 80 mg, or rosuvastatin 20 or 40 mg or at maximally tolerated dose of those statins) with or without other LMT.

All patients were randomized 1:1 to receive either PRALUENT 75 mg once every two weeks (Q2W) or placebo Q2W. At month 2, if additional LDL-C lowering was required based on pre-specified LDL-C criteria (LDL-C ≥1.29 mmol/L), PRALUENT was adjusted to 150 mg Q2W. For patients who had their dose adjusted to 150 mg Q2W and who had two consecutive LDL-C values below 0.65 mmol/L, down-titration from 150 mg Q2W to 75 mg Q2W was performed. Patients receiving 75 mg Q2W who had two consecutive LDL-C values below 0.39 mmol/L were switched to placebo in a blinded fashion. In total, 2615 (27.7%) patients receiving PRALUENT required dose adjustment to 150 mg Q2W; 805 (30.8%) subsequently were down-titrated to 75 mg Q2W. Overall, 730 (7.7%) patients receiving PRALUENT were switched to placebo. A total of 99.5% of patients were followed for survival until the end of the trial.

The primary efficacy endpoint was the time from randomization to first occurrence of one of the following clinical events, as determined by the Clinical Events Committee: coronary heart disease (CHD)

death (including “undetermined causes of death”), any non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke (including “stroke not otherwise specified”), and unstable angina (UA) requiring hospitalization. The final analysis was scheduled to occur when 1613 events had occurred or 24 months after the last date of randomization (excluding China), whichever occurred last.

The index ACS event was a myocardial infarction in 83.2% of patients (34.6% STEMI, 48.6% NSTEMI) or an episode of unstable angina in 16.8% of patients. Prior to the index ACS event, 19.2% of patients had a myocardial infarction and 22.7% had coronary revascularization procedures (CABG/PCI). Most patients (88.8%) were receiving high intensity statin therapy with or without other LMT at randomization. The mean LDL-C value at baseline was 2.39 mmol/L; a total of 28.8% of patients had diabetes at baseline.

PRALUENT significantly reduced the risk of the primary composite endpoint: time-to-first occurrence of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, or unstable angina (UA) requiring hospitalization (p =0.0003) (see Table 6).

Table 6 – Efficacy of PRALUENT in Patients with Established Cardiovascular Disease

(ITT Population)

The Kaplan-Meier estimates of the cumulative incidence of the primary endpoint over time for the overall patient population is presented in Figure 2.

Figure 2 – Major Atherosclerotic Cardiovascular Disease Events: Cumulative Incidence Over 4 Years in ODYSSEY OUTCOMES

Primary Hyperlipidemia

Table 7 – Summary of Trial Design and Patient Demographics in Primary Hyperlipidemia

Study demographics and trial design

The efficacy of alirocumab was investigated in five double-blind placebo-controlled phase 3 trials that enrolled 3499 patients; 36% were patients with heterozygous familial hypercholesterolemia (HeFH) and 54% were non-FH patients who had clinical atherosclerotic cardiovascular disease. Three of the five studies were conducted exclusively in patients with heterozygous familial hypercholesterolemia (HeFH). All patients were taking background lipid-modifying therapy (LMT) consisting of a maximally tolerated dose of statin, with or without other lipid-modifying therapies. In the trials that enrolled patients with HeFH, the diagnosis of HeFH was made either by genotyping or clinical criteria (“definite FH” using either the Simon Broome or WHO/Dutch Lipid Network criteria). All trials were at least 52 weeks in duration with the primary efficacy endpoint measured at week 24 (mean percent change in LDL-C from baseline).

Two studies (LONG TERM and HIGH FH), involving a total of 2416 patients, were performed with a 150 mg every 2 weeks (Q2W) dose only. Three studies (COMBO I, FH I and FH II) were performed with a dose of 75 mg Q2W, and criteria-based up-titration to 150 mg Q2W at week 12 in patients who did not achieve their pre-defined target LDL-C based on their level of CV risk at week 8.

The efficacy of PRALUENT was also investigated in three ezetimibe-controlled trials (COMBO II, ALTERNATIVE, MONO) using an initial dose of 75 mg Q2W followed by criteria-based up-titration to 150 mg Q2W at week 12, with the primary efficacy endpoint measured at week 24 (mean percent change from baseline in LDL-C).

Another double-blind, placebo-controlled, 48-week trial (CHOICE I) enrolled 547 patients on maximally tolerated dose of statin who received PRALUENT 300 mg every 4 weeks (Q4W), 75 mg every 2 weeks (Q2W) or placebo, with criteria-based adjustment to 150 mg Q2W in the PRALUENT arms at week 12. The co-primary efficacy endpoints were evaluated at week 24 and from weeks 21 to 24 (mean percent change in LDL-C from baseline).

LONG TERM study

This multicentre, randomized, double-blind, placebo-controlled, 18-month study included 2341 patients (1553 patients in the alirocumab group and 788 patients in the placebo group) with HeFH or non-FH on a maximally tolerated dose of statin, with or without other lipid-modifying therapy. Patients received either alirocumab at a dose of 150 mg Q2W or placebo in addition to their existing lipid-modifying therapy.

The LONG TERM study included 17.7% HeFH patients and 68.6% non-FH patients with clinical atherosclerotic cardiovascular disease. The mean age was 60.5 years (range 18-89), 37.8% were women, 93% were Caucasian, 3% were Black, and 5% were Hispanic/Latino. The mean LDL-C at baseline was 3.15 mmol/L (122 mg/dL).

The proportion of patients who prematurely discontinued study drug prior to the 24-week endpoint was 8% among those treated with PRALUENT and 8% among those treated with placebo.

At week 24, the treatment difference between PRALUENT and placebo in mean LDL-C percent change was -58.5 % (95% CI:-61.1%, -55.8%; p-value: ˂0.0001) (see Table 8and Figure 3).

Table 8 – Mean Percent Change from Baseline and Difference^a from Placebo in Lipid Parameters at

Week 12 and Week 24 in the LONG TERM Study^b

Figure 3 – Mean Percent Change from Baseline in LDL-C over 52 weeks in the LONG TERM study^a

^a The means were estimated based on all randomized patients, with multiple imputation of missing data taking into account treatment adherence

^b Number of patients with observed data

COMBO I study

A multicentre, randomized, double-blind, placebo-controlled 52 week study included 316 patients (209 in the alirocumab group and 107 patients in the placebo group) categorized as very high CV risk with hypercholesterolemia on a maximally tolerated dose of statin, with or without other lipid-modifying therapy who required additional LDL-C reduction. Patients received either 75 mg alirocumab Q2W or placebo in addition to their existing lipid-modifying therapy. Dose up-titration of alirocumab to 150 mg Q2W occurred at week 12 in patients with LDL-C ≥1.81 mmol/L (70 mg/dL).

The mean age was 63 years (range 39-87), 34.2% were women, 82% were Caucasian, 16% were Black, and 11% were Hispanic/Latino. Overall 84% of patients had clinical atherosclerotic cardiovascular disease. The mean baseline LDL-C was 2.63 mmol/L (102 mg/dL).

The dose was up-titrated to 150 mg Q2W in 32 of 191 (16.8%) of patients treated beyond 12 weeks.

The proportion of patients who prematurely discontinued study drug prior to the 24-week endpoint was 11% among those treated with PRALUENT and 12% among those treated with placebo.

At week 24, the mean treatment difference from placebo in LDL-C percent change from baseline was - 42.7% (95% CI: - 49.9%, - 35.4%; p-value: ˂ 0.0001) (see Table 9).

Table 9 – Mean percent Change from Baseline and Difference^a from Placebo in Lipid Parameters at Week 12 and Week 24 in the COMBO I Study^b

FH I and FH II studies

Two multicentre, placebo-controlled, double-blind 18-month studies included 735 patients (490 in the alirocumab group and 245 patients in the placebo group) with HeFH receiving a maximally tolerated dose of statin, with or without other lipid-modifying therapy. The trials were similar with regards to both design and eligibility criteria. Patients received either alirocumab 75 mg Q2W or placebo in addition to their existing lipid-modifying therapy. Dose up-titration of alirocumab to 150 mg Q2W occurred at week 12 in patients with LDL-C ≥ 1.81 mmol/L (70 mg/dL).

Overall, the mean age was 52 years (range 20-87), 45% were women, 94% were Caucasian, 1% were Black, and 3% were Hispanic/Latino. The proportion of patients in FH I study and in the FH II study with clinical atherosclerotic cardiovascular disease was 51.2% and 38.3% respectively. The mean baseline LDL-C was 3.74 mmol/L (144.6 mg/dL) in FH I study and 3.48 mmol/dL (134.4 mg/dL) in FH II study. The dose was up-titrated beyond week 12 in 135 of 311 patients (43.4%) in FHI study and in 61 of 158 patients (38.6%) in FH II study.

The proportion of patients who prematurely discontinued study drug prior to the 24-week endpoint was 6.5% among those treated with PRALUENT and 5.5% among those treated with placebo in the FH I study and 4.8% among those treated with PRALUENT and 2.4% among those treated with placebo in the FH II study.

At week 24, the mean treatment difference from placebo in LDL-C percent change from baseline in FH I study was -56.3% (95% CI: -61.8%, -50.7%; p-value: ˂ 0.0001) (see Table 10 and Figure 4). At week 24, the mean treatment difference from placebo in LDL-C percent change from baseline in FH II study was -50.2% (95% CI:-57.1%, -43.2%; p-value: ˂ 0.0001) (see Table 10 and Figure 5).

Table 10 – Mean Percent Change from Baseline and Difference^a from Placebo in Lipid Parameters at Week 12 and Week 24 in Studies FH I^b and FH II^b

Figure 4 – Mean Percent Change from Baseline in LDL-C over 52 weeks in FH I Study^a

^a The means were estimated based on all randomized patients, with multiple imputation of missing data taking into account treatment adherence

^b Number of patients with observed data

Figure 5 – Mean Percent Change from Baseline in LDL-C over 52 weeks in FH II Study^a

^a The means were estimated based on all randomized patients, with multiple imputation of missing data taking into account treatment adherence

^b Number of patients with observed data

HIGH FH study

HIGH FH was a multicentre, randomized, double-blind, placebo-controlled 18-month study that included 107 HeFH patients (72 patients in the alirocumab group and 35 patients in the placebo group) on a maximally tolerated dose of statin, with or without other lipid-modifying therapies, and a baseline LDL-C ≥ 4.14 mmol/L (160 mg/dL). Patients received either alirocumab at a dose of 150 mg Q2W or placebo in addition to their existing lipid-modifying therapy.

The mean age was 50.6 years (range 18-80), 46.7% were women, 88% were Caucasian, 2% were Black, and 6% were Hispanic/Latino. Overall, 50% of patients had clinical atherosclerotic cardiovascular disease. Mean baseline LDL-C was 5.08 mmol/L (196.3 mg/dL) in the alirocumab group and 5.2 mmol/L (201.0 mg/dL) in the placebo group.

The proportion of patients who discontinued study drug prior to the 24-week endpoint was 10% among those treated with PRALUENT and 0% among those treated with placebo.

At week 24, the mean treatment difference from placebo in LDL-C percent change from baseline was - 36.3% (95% CI: -48.5%, -24.2%; p-value: ˂ 0.0001) (see Table 11).

Table 11 – Mean percent Change from Baseline and Difference^a from Placebo in Lipid Parameters at Week 12 and Week 24 in the HIGH FH Study^b

CHOICE I

CHOICE I was a double-blind, placebo-controlled 48-week trial that randomly assigned 458 patients to PRALUENT 300 mg every 4 week dosing regimen (Q4W), 115 patients to PRALUENT 75 mg every 2 weeks (Q2W), and 230 patients to placebo. All 803 patients had hypercholesterolemia and were receiving concomitant statins (68.1%) or other lipid modifying therapy (39.8%). The primary efficacy endpoint was measured at week 24 (mean percent change in LDL-C from baseline). At week 12, if additional LDL-C lowering was required based on pre-specified LDL-C criteria, PRALUENT was adjusted to 150 mg Q2W in the PRALUENT treatment groups for the remainder of the trial. Approximately 20% of patients treated with PRALUENT 75 mg Q2W or 300 mg Q4W for at least 12 weeks required dose adjustment to 150 mg Q2W.

The mean age was 61years (range 21-88), 42 % were women, 87% were Caucasian, 11% were Black, and 3% were Hispanic/Latino. Overall, 64% of patients had atherosclerotic cardiovascular disease; 27% of patients had type 2 diabetes at baseline. The proportion of patients who discontinued study drug prior to the 24-week endpoint was 12% among those treated with PRALUENT 300 mg Q4W, 14% among those treated with PRALUENT 75 mg Q2W and 15% among those treated with placebo.

In the cohort of patients on background statin, the mean LDL-C at baseline was 2.92 mmol/L.

At week 24, the treatment difference between initial assignment to PRALUENT 300 mg Q4W and placebo in mean percent change from baseline in LDL-C was -56% (97.5% CI: -62%, -49%; p-value: <0.0001), and the treatment difference between initial assignment to PRALUENT 75 mg Q2W and placebo in mean percent change in LDL-C from baseline was -48% (97.5% CI: -57%, -39%).

In the cohort of patients not treated with a concomitant statin, the mean LDL-C at baseline was 3.67 mmol/L (142 mg/dL).

At week 24, the treatment difference between initial assignment to PRALUENT 300 mg Q4W and placebo in mean percent change in LDL-C from baseline was - 48% (97.5% CI: -56%, -39%; p-value: <0.0001), and the treatment difference between initial assignment to PRALUENT 75 mg Q2W and placebo in mean percent change in LDL-C from baseline was -45% (97.5% CI: -57%, -34%; p-value: <0.0001).

In the subgroup of patients with pre-existing type II diabetes mellitus, percent reduction in LDL-C was consistent with the overall population.

Neurocognitive Function (R727-CL-1532)

A 96 week, randomized, double-blind, placebo‑controlled trial evaluated the effect of PRALUENT on neurocognitive endpoints after 96 weeks of treatment (1.8 years) in patients aged 40 to 85 years old with heterozygous familial hypercholesterolemia (HeFH) or non-familial hypercholesterolemia, at high or very high cardiovascular risk, who did not have cognitive impairment or dementia. Nearly all patients (> 91.3%) were taking background lipid-modifying therapy (LMT) consisting of a maximally tolerated dose of statin, with or without other LMTs.

Neurocognitive function was assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB). A total of 2171 patients were randomized; 1087 patients were treated with alirocumab 75 mg and/or 150 mg every 2 weeks and 1084 patients were treated with placebo. A majority (>80%) of patients in each group completed the 96-week, double-blind treatment period.

After 96 weeks of treatment, PRALUENT was non-inferior to placebo on select cognitive function domains. The percentage of patients who reported neurocognitive disorders was 1.3% in the PRALUENT treatment group and 1.7% in the placebo group.

COMBO II study

COMBO II study was a multicentre, randomized, double-blind, ezetimibe-controlled 2 year study that included 720 patients (479 patients in the alirocumab group and 241 patients in the ezetimibe group)

categorized as very high CV risk with hypercholesterolemia, on a maximally tolerated dose of statin. Patients received either alirocumab 75 mg Q2W or ezetimibe 10 mg once daily in addition to their existing statin therapy. Dose up-titration of alirocumab to 150 mg Q2W occurred at week 12 in patients with LDL-C ≥ 1.81 mmol/L (70 mg/dL); the dose was up-titrated to 150 mg Q2W in 82 (18%) of 446 patients treated with PRALUENT for at least 12 weeks.

The mean age was 61.6 years (range 29-88), 26.4% were women, 84.7% were Caucasian, 3.9% were Black, and 2.8% were Hispanic/Latino. Overall 90.1% of patients had clinical atherosclerotic cardiovascular disease; 30.7% of patients had type 2 diabetes at baseline. Mean baseline LDL-C was 2.81 mmol/L (108.6 mg/dL) in the alirocumab group and 2.7 mmol/L (104.6 mg/dL) in the ezetimibe group. The dose was up-titrated to 150 mg Q2W in 82 of 446 (18.4%) of patients treated beyond 12 weeks.

The proportion of patients who prematurely discontinued study drug prior to the 24-week endpoint was 8.6% among those treated with PRALUENT and 9.5% among those treated with ezetimibe.

At week 24, the mean percent change from baseline in LDL-C was -47.8% with PRALUENT and -20.1% with ezetimibe, and the mean treatment difference from ezetimibe in LDL-C percent change from baseline was - 27.7% (95% CI: -32.5%, -22.9%, ; p-value: ˂ 0.0001).

In the subgroup of patients with pre-existing type II diabetes mellitus, percent reduction in LDL-C was consistent with the overall population.

ALTERNATIVE study

ALTERNATIVE study was a multicentre, double-blind, ezetimibe-controlled trial in patients for whom the maximally tolerated daily dose of statin was contraindicated due to skeletal muscle-related symptoms, with 126 patients randomly assigned to PRALUENT 75 mg Q2W/150 mg Q2W and 125 patients to ezetimibe 10 mg/day. At week 12, if additional LDL-C lowering was required based on pre-specified LDL-C criteria, PRALUENT was up-titrated to 150 mg Q2W for the remainder of the trial. The dose was up-titrated to 150 mg Q2W in 54 (50%) of 109 patients treated with PRALUENT for at least 12 weeks.

There were 48.7% of patients that were on concomitant non-statin lipid modifying therapy other than ezetimibe. The mean age was 63 years (range 31-88), 45% were women, 94% were Caucasian, 4% were Black, and 2% were Hispanic/Latino; 23.9% of patients had type 2 diabetes at baseline. Mean baseline LDL-C was 4.9 mmol/L (191 mg/dL).

The proportion of patients who prematurely discontinued study drug prior to the 24-week endpoint was 24% among those treated with PRALUENT and 33% among those treated with ezetimibe.

At week 24, the mean percent change from baseline in LDL-C was -44% with PRALUENT and -13% with ezetimibe, and the treatment difference between PRALUENT and ezetimibe in mean LDL-C percent change was -30% (95% CI: -37%, -24%; p-value: ˂0.0001).

In the subgroup of patients with pre-existing type II diabetes mellitus, percent reduction in LDL-C was consistent with the overall population.

MONO study

MONO study was a multicentre, double-blind, ezetimibe-controlled trial in patients with a moderate CV risk, not taking statins or other lipid-modifying therapies, and a baseline LDL-C between 2.59-4.9 mmol/L (100 mg/dL to 190 mg/dL) that randomly assigned 52 patients to PRALUENT 75 mg Q2W and 51 patients to ezetimibe 10 mg/day. At week 12, if additional LDL-C lowering was required based on pre-specified LDL-C criteria, PRALUENT was up-titrated to 150 mg Q2W for the remainder of the trial. The dose was up-titrated to 150 mg Q2W in 14 (30%) of 46 patients treated with PRALUENT for at least 12 weeks.

The mean age was 61 years (range 49-72), 46% were women, 89% were Caucasian and 12% were Black. Mean baseline LDL-C was 141 mg/dL. The proportion of patients who prematurely discontinued study drug prior to the 24-week endpoint was 15% among those treated with PRALUENT and 14% among those treated with ezetimibe.

At week 24, the mean percent change from baseline in LDL-C was -45% with PRALUENT and -14% with ezetimibe, and the treatment difference between PRALUENT and ezetimibe in mean LDL-C percent change was -31% (95% CI: -40%, -22%; p-value: ˂0.0001).

16. Non-Clinical Toxicology

No significant adverse effects were observed in rats and cynomolgus monkeys when administered alirocumab by subcutaneous or intravenous injection up to dose levels of 75 mg/kg QW for 6 months.

There were no additive or synergistic adverse effects when alirocumab was administered in combination with atorvastatin to cynomolgus monkeys up to dose levels of 75/mg/kg QW and 40 mg/kg QD, respectively, for 3 months.

Carcinogenicity, mutagenicity and genotoxicity studies have not been conducted with alirocumab. There were no adverse effects on surrogate markers of fertility (e.g. estrous cyclicity, testicular volume or sperm parameters) up to doses of 75 mg/kg QW included in a 26-week chronic subcutaneous toxicology study in sexually-mature monkeys. In addition, there were no alirocumab-related anatomic pathology or histopathology findings in reproductive tissues in any rat or monkey toxicology study.

No effects on embryo-fetal development were observed in Sprague Dawley rats up to doses of 75 mg/kg by subcutaneous route on gestational day 6 and 12. Studies in monkeys showed that alirocumab crosses the placental barrier and is pharmacologically active in infants exposed during organogenesis through parturition. Dose-related decreases in T-cell dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) were observed at doses ≥ 15 mg/kg QW in offspring of exposed mothers at 4 to 6 months of age, suggesting a suppression of humoral immune response. Recovery of infant immune function was not assessed. Studies in monkeys did not demonstrate any additional embryo-fetal, pre- or postnatal or maternal effects up to doses of 75 mg/kg QW.